AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors.

Abstract

HER3 is a unique member of the EGFR family of tyrosine kinases, which is broadly expressed in several cancers, including breast, lung, pancreatic, colorectal, gastric, prostate, and bladder cancers and is often associated with poor patient outcomes and therapeutic resistance. U3-1402/Patritumab-GGFG-DXd is the first successful HER3-targeting antibody-drug conjugate (ADC) with clinical efficacy in non-small cell lung cancer. However, over 60% of patients are nonresponsive to U3-1402 due to low target expression levels and responses tend to be in patients with higher target expression levels. U3-1402 is also ineffective in more challenging tumor types such as colorectal cancer. AMT-562 was generated by a novel anti-HER3 antibody Ab562 and a modified self-immolative PABC spacer (T800) to conjugate exatecan. Exatecan showed higher cytotoxic potency than its derivative DXd. Ab562 was selected because of its moderate affinity for minimizing potential toxicity and improving tumor penetration purposes. Both alone or in combination therapies, AMT-562 showed potent and durable antitumor response in low HER3 expression xenograft and heterogeneous patient-derived xenograft/organoid models, including digestive system and lung tumors representing of unmet needs. Combination therapies pairing AMT-562 with therapeutic antibodies, inhibitors of CHEK1, KRAS, and tyrosine kinase inhibitor showed higher synergistic efficacy than Patritumab-GGFG-DXd. Pharmacokinetic and safety profiles of AMT-562 were favorable and the highest dose lacking severe toxicity was 30 mg/kg in cynomolgus monkeys. AMT-562 has potential to be a superior HER3-targeting ADC with a higher therapeutic window that can overcome resistance to generate higher percentage and more durable responses in U3-1402-insensitive tumors.

• Authors: Weining Weng, Tao Meng, Junyi Pu, Linjie Ma, Yi Shen, Zhaohui Wang, Rong Pan, Mingqiao Wang, Caiwei Chen, Lijun Wang, Jianjian Zhang, Biao Zhou, Siyuan Shao, Yu Qian, Shuhui Liu, Wenhao Hu, Xun Meng
• Journal: Molecular cancer therapeutics (Mol Cancer Ther) Vol. 22 Issue 9 Pg. 1013-1027 (09 05 2023) ISSN: 1538-8514 [Electronic] United States
• PMID: 37302522 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: ©2023 The Authors; Published by the American Association for Cancer Research.

Chemical References

• Immunoconjugates
• Receptor, ErbB-3
• ErbB Receptors

Topics

• Male
• Humans
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Lung Neoplasms (drug therapy)
• Immunoconjugates (pharmacology, therapeutic use)
• Receptor, ErbB-3
• ErbB Receptors
• Cell Line, Tumor